权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Utility of Deep Sequencing for Detecting Heteroresistant Mycobacterium tuberculosis Infections among HIV-infected Persons

深度测序在检测 HIV 感染者中异抗性结核分枝杆菌感染中的应用

基本信息

批准号：
9115984
负责人：
Sanghyuk Sam Shin
金额：
$ 8.63万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-08-01 至 2017-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9115984
关键词：
Affect Alleles Botswana Cause of Death Clinical Cohort Studies Collaborations Country DNA Detection Development Diagnosis Diagnostic Procedure Diagnostic tests Drug resistance Drug resistance in tuberculosis Early Diagnosis Early treatment Enrollment Failure Foundations Frequencies Future Genes Genetic Genetic study Goals HIV HIV drug resistance HIV/TB Health Infection Intermediate resistance Lead Life Liquid substance Methodology Methods Minority Morbidity - disease rate Mutation Mycobacterium tuberculosis Newly Diagnosed Outcome Parents Pathogenesis Patients Persons Pharmaceutical Preparations Process Public Health Reading Research Research Infrastructure Resistance Resistance development Resources Rifampin Risk Sample Size Sampling Scientific Advances and Accomplishments Specimen Sputum Technology Testing Time Treatment outcome Tuberculosis Variant clinical practice deep sequencing high risk improved innovation insight isoniazid mortality mutant next generation novel diagnostics population based predicting response prospective rapid detection rapid diagnosis research study tool tuberculosis drugs tuberculosis treatment

项目摘要

DESCRIPTION (provided by applicant): The proposed study will help to establish methods for rapid detection of heteroresistant Mycobacterium tuberculosis (MTB) infections among HIV-infected TB patients. Heteroresistant MTB infections involve both drug-resistant and drug-susceptible types of MTB. A person with heteroresistant MTB infection is more likely to develop fully drug-resistant TB, which can cause poor treatment outcomes, increasing morbidity and mortality. People living with HIV appear to be especially at high risk for acquiring heteroresistan TB infections, and TB remains the leading cause of death among HIV-infected persons in resource poor countries, including Botswana. Recent developments in sequencing technology (deep sequencing) could be a powerful tool for rapidly detecting heteroresistant MTB infections. However, no study has systematically evaluated deep sequencing for detecting heteroresistance among TB patients in a clinical setting. Improved understanding of heteroresistance will contribute to significant improvements in TB morbidity and mortality and advance scientific understanding of TB. We propose to conduct an exploratory substudy of TB/HIV co-infected patients enrolled in an ongoing population-based TB research study in Botswana. We will identify and enroll 200 newly diagnosed TB patients on first-line therapy. We will collect sputum samples at enrollment and after 2 months of treatment. We will use deep sequencing of MTB DNA to look for heteroresistance. There are two specific aims to our proposal. Aim 1. We will determine whether direct sequencing from sputum specimen increases the detection of heteroresistant MTB infections compared to sequencing done on MTB culture samples. Aim 2. We will determine whether heteroresistant MTB infection status is predictive of response to TB treatment among patients on first-line TB therapy. This proposed research will be the first to systematically evaluate the use of deep sequencing to detect heteroresistant MTB infections, potentially improving clinical practice by allowing for rapid, early detection of heteroresistant infections and informing treatment decisions accordingly.